drugset / Trial / NCT02465814

Assess Safety and Efficacy of Vilaprisan in Patients With Uterine Fibroids

NCT02465814

Phase 2 Completed 120 enrolled Bayer
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The study is performed to assess the efficacy of Vilaprisan (BAY1002670) in patients with uterine fibroids compared to placebo and ulipristal. It is also aimed to evaluate the safety of vilaprisan in subjects with uterine fibroids. Further, data on population pharmacokinetic (PK)/ pharmacodynamic (PD) relationship for vilaprisan in subjects with uterine fibroids will be supplemented.

Timeline

Start
2015-06
Primary completion
2016-10
Completion
2016-10

Drugs

EvaluationDrugModalityDoseRoute
Comparator Ulipristal Acetate Unknown 5 mg
Subject Vilaprisan Other / unclassified 2 mg

Indications